Skip to content

Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517295-37-00
Acronym
Uni-Koeln-4299
Enrollment
280
Registered
2024-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low and intermediate risk neuroblastoma

Brief summary

Event-free survival (EFS): Time from diagnosis to event or last follow-up for patients without event; event is defined as death for all reasons, progression and relapse following previous complete remission or secondary malignant disease

Detailed description

Overall Survival (OS): Because of the importance for the individual patient OS has been chosen as secondary endpoint., Risk factors to impact on EFS and OS: The risk factors age at diagnosis, stage according to INSS and INRG, and copy number alterations of selected genes have been implemented in the INRG classification. These factors will be assessed by multivariate and subgroup analysis. Moreover, the description of patients’ cohorts by these risk factors is mandatory for international comparison of the trial results., Response: In neuroblastoma, response to trial treatment is not clearly correlated to outcome. In this trial, response to trial treatment will be compared to historical controls, with a special focus to the cohort with reduced treatment (group C)., Regression: The percentage of spontaneous regression will be described in patients where the residual primary is observed without cytotoxic treatment and compared to historical controls., Incidence rates of toxic events: The administered chemotherapy cycles are known to cause treatment related side effects. To estimate the burden for the patients, kind and intensity of side effects will be compared to historical controls and between the patient groups A-C., Additional molecular analysis: The impact of clinical and molecular risk factors such as copy number alterations, telomere maintenance status and mutation status of candidate genes on EFS and OS will be analyzed., Group D, relapsed patients: Outcome of patients with relapse or progression of neuroblastoma diagnosed at the age < 18 months with unfavorable classification.

Interventions

DRUGMELPHALAN
DRUGFILGRASTIM
DRUGVINCRISTINE SULFATE
DRUGCLONAZEPAM
DRUGBUSULFAN
DRUGCYCLOPHOSPHAMIDE
DRUGETOPOSIDE
DRUGCARBOPLATIN
DRUGMESNA
DRUGDOXORUBICIN HYDROCHLORIDE
DRUGETOPOSIDE PHOSPHATE
DRUGDACARBAZINE
DRUGIFOSFAMIDE
DRUGCISPLATIN

Sponsors

University Of Cologne
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Event-free survival (EFS): Time from diagnosis to event or last follow-up for patients without event; event is defined as death for all reasons, progression and relapse following previous complete remission or secondary malignant disease

Secondary

MeasureTime frame
Overall Survival (OS): Because of the importance for the individual patient OS has been chosen as secondary endpoint., Risk factors to impact on EFS and OS: The risk factors age at diagnosis, stage according to INSS and INRG, and copy number alterations of selected genes have been implemented in the INRG classification. These factors will be assessed by multivariate and subgroup analysis. Moreover, the description of patients’ cohorts by these risk factors is mandatory for international comparison of the trial results., Response: In neuroblastoma, response to trial treatment is not clearly correlated to outcome. In this trial, response to trial treatment will be compared to historical controls, with a special focus to the cohort with reduced treatment (group C)., Regression: The percentage of spontaneous regression will be described in patients where the residual primary is observed without cytotoxic treatment and compared to historical controls., Incidence rates of toxic events: The a

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026